Triomics raises $15M Series A to Revolutionize Cancer Clinical Trials Matching

Triomics raises $15M Series A to Revolutionize Cancer Clinical Trials Matching

Triomics, a leading creative AI startup, has raised $15 million in Series A to accelerate its mission to automate cancer clinical trials. Founded by former MIT biotech researcher Saram Khan and AI scientist Hartoraj Singh, Triomics aims to address a critical gap in cancer care by helping doctors match patients with appropriate trials. The time taken is to be reduced considerably.

Despite the abundance of clinical trials, only a small fraction of eligible patients enroll, largely due to the time-consuming process of trial matching. Triomics' generative AI technology promises to streamline this process, allowing oncologists to rapidly identify relevant trials tailored to each patient's unique profile.

The company's platform, OncoLLM, leverages advances in generative AI and large language models (LLMs) to extract relevant data from electronic health records (EHR), enabling rapid identification of appropriate trials. By automating this laborious task, Triomics aims to empower clinical staff to efficiently match patients with trials, potentially saving lives and advancing cancer research.

Since its launch in 2021, Triomics has gained significant traction, with six cancer centers and hospitals actively using or piloting its platform. With Series A funding from Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator, Triomics plans to further develop its platform and expand its customer base, expanding its reach by the end of the year. Doubles it.

While Triomics is initially focused on matching clinical trials, Khan emphasizes that the platform offers broader applications beyond that scope. Clinical staff can leverage OncoLLM for a variety of use cases, from preparing patient visits to submitting cancer data to regulatory agencies. Triomics aims to be a comprehensive solution for cancer centers, leveraging AI to increase efficiency and improve patient outcomes.

While Triomics faces competition in the AI ​​clinical trial matching space, Khan believes its focus on processing large data sets, especially for cancer centers, sets it apart. With its innovative approach and strong investor backing, Triomics is poised to make a significant impact in the fight against cancer.

About the Author

Leave a Reply